Advertisement

Drugs & Therapy Perspectives

, Volume 12, Issue 7, pp 1–5 | Cite as

Raloxifene: the first selective estrogen receptor modulator for postmenopausal osteoporosis

New Drugs and Disease Management
  • 8 Downloads

Keywords

Bone Mineral Density Postmenopausal Woman Endometrial Cancer Alendronate Raloxifene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998 Apr; 12(4): 335–41PubMedCrossRefGoogle Scholar
  2. 2.
    Carlson R. MORE not yet enough for raloxifene and breast cancer prevention. Inpharma 1998 Jun 13; 1141: 13–4Google Scholar
  3. 3.
    Raloxifene prescribing information. Eli Lilly and Company. Indianapolis, USA, 1997Google Scholar
  4. 4.
    British National Formulary. No. 35. London: The Pharmaceutical Press, 1998 Mar: 334–5Google Scholar
  5. 5.
    PDR Generics. 4th ed. Montvale (NJ): Medical Economics, 1998: 71–5Google Scholar
  6. 6.
    Delmas PD, Bjarnason NH, Mitlak B, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7PubMedCrossRefGoogle Scholar
  7. 7.
    Gunness M, Prestwood K, Lu Y, et al. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCl and Premarin in postmenopausal women [abstract no. OR4-2]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 67Google Scholar
  8. 8.
    Walsh BW, Kuller LH, Wild RA, et al. The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women [abstract]. Atherosclerosis 1997; 134 (1,2): 182CrossRefGoogle Scholar
  9. 9.
    Huster W, Shah A, Cohen F, et al. Effect of raloxifene on the endometrium in healthy postmenopausal women. The North American Menopause Society 8th Annual Meeting; 1997 Sep 4–6; BostonGoogle Scholar
  10. 10.
    Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458–64PubMedCrossRefGoogle Scholar
  11. 11.
    Scheele W, Symanowski SM, Neale S, et al. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women [abstract no. P#-246]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 498Google Scholar
  12. 12.
    Alendronic acid: effective therapy for postmenopausal osteoporosis. Drugs Ther Perspect 1997 Jul 7; 10(1); 1–5Google Scholar
  13. 13.
    Prestwood KM. Raloxifene: a viewpoint. Drugs Aging 1998 Apr; 12(4): 342CrossRefGoogle Scholar
  14. 14.
    Hannover Bjarnason N. Raloxifene: a viewpoint. Drugs Aging 1998 Apr; 12(4): 342CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Personalised recommendations